EXCELLENCE NESSUAH UPS TEVA PRICE TARGET

Excellence Nessuah has raised its price target for Israeli generic pharmaceuticals company Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ; TASE: TEVA) to $48. This compares with a current market price of $40.17, at which Teva has a market cap of $25.11 billion. Analyst Richard Gussow says that the recently-completed $8.8 billion acquisition of Miami-based Ivax will further strengthen Teva's already advantageous position in a market about to enjoy something of a boom, with a high number of drug patents close to expiry, and yet Teva is not traded at a premium.
Globes Online